What one share of AnaptysBio holds
AnaptysBio manages the financial collaborations for a PD-1 antagonist (Jemperli (dostarlimab-gxly) or “Jemperli”) with TESARO, Inc. (“Tesaro”), an oncology-focused biopharmaceutical subsidiary of GSK (Tesaro and GSK are hereinafter referred to, collectively, as “GSK”) and an IL-36R antagonist (“Quimilza” formerly referred to as imsidolimab) with Vanda Pharmaceuticals Inc.
AnaptysBio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $7.07 |
|---|---|
| Profit | $5.83 |
| Cash and investments | $4.50 |
| Book value | $0.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | $6.89 | −$2.12 | $0.09 | −$3.89 | — | −$13.79 |
| 2016 | $6.33 | −$1.62 | $0.02 | −$3.44 | — | −$14.43 |
| 2017 | $0.51 | −$1.52 | $0.01 | −$1.00 | — | $12.93 |
| 2018 | $0.20 | −$2.50 | $0.04 | −$2.01 | — | $18.07 |
| 2019 | $0.30 | −$3.60 | $0.03 | −$2.60 | — | $14.86 |
| 2020 | $2.75 | −$0.73 | $0.02 | −$0.54 | — | $14.50 |
| 2021 | $2.30 | −$2.11 | $0.05 | −$1.72 | — | $12.89 |
| 2022 | $0.37 | −$4.57 | $0.01 | −$2.63 | — | $9.19 |
| 2023 | $0.64 | −$6.08 | $0.03 | −$4.52 | — | $3.31 |
| 2024 | $3.09 | −$4.92 | $0.01 | −$4.59 | — | $2.33 |
| 2025 | $7.76 | −$0.44 | $0.00 | $0.65 | — | $1.33 |
Common questions about AnaptysBio
How much does one share of AnaptysBio earn?
Over the last 12 months, each share of AnaptysBio earned $5.83 of profit on $7.07 of sales, keeping about 82¢ of every $1 (profit margin).
Does AnaptysBio pay a dividend?
AnaptysBio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is AnaptysBio’s book value per share?
AnaptysBio’s book value is $0.36 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of AnaptysBio have?
Each share of AnaptysBio has $4.50 of cash and investments, as of June 30, 2026.
Has AnaptysBio bought back shares?
AnaptysBio’s share count rose about 1085% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.